WO2006032164A1 - Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci - Google Patents

Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci Download PDF

Info

Publication number
WO2006032164A1
WO2006032164A1 PCT/CN2004/001081 CN2004001081W WO2006032164A1 WO 2006032164 A1 WO2006032164 A1 WO 2006032164A1 CN 2004001081 W CN2004001081 W CN 2004001081W WO 2006032164 A1 WO2006032164 A1 WO 2006032164A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
ethyl
group
piperidine
Prior art date
Application number
PCT/CN2004/001081
Other languages
English (en)
Chinese (zh)
Inventor
Song Li
Jizhou Liu
Lili Wang
Zhibing Zheng
Hongying Liu
Chengmai Ruan
Yunde Xie
Beifen Shen
Original Assignee
Beijing Molecule Science And Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Molecule Science And Technology Co., Ltd. filed Critical Beijing Molecule Science And Technology Co., Ltd.
Priority to PCT/CN2004/001081 priority Critical patent/WO2006032164A1/fr
Publication of WO2006032164A1 publication Critical patent/WO2006032164A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

L'invention concerne des dérivés de 2-indolinone substituée en position 1 et 3 de formule (I), le procédé de préparation de ceux-ci, une composition pharmaceutique comprenant ceux-ci et l'utilisation de ceux-ci dans la préparation de médicaments antinéoplasiques, dans laquelle n est 2 ou 3 ; R1 est un hétéroaryle sélectionné dans le groupe constitué des groupes furyle, thiényle, pyrrolyle, pyridyle et similaires ; R2 est sélectionné parmi un hydrogène, un halogène, un cyano et similaires ; R3 et R4 sont sélectionnés indépendamment dans le groupe constitué d'alkyles en C1∼C6, d'alcényles en C2∼C7 ; ou bien R3 et R4, ainsi que l'atome d'azote auquel ils sont attachés, se combinent pour former un hétérocycle à 4∼6 éléments, lequel est sélectionné dans le groupe constitué des groupes tétrahydropyrrolyle, pipéridyle, morpholinyle, pipérazine ou nitrométhylpipérazine.
PCT/CN2004/001081 2004-09-23 2004-09-23 Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci WO2006032164A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/001081 WO2006032164A1 (fr) 2004-09-23 2004-09-23 Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/001081 WO2006032164A1 (fr) 2004-09-23 2004-09-23 Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
WO2006032164A1 true WO2006032164A1 (fr) 2006-03-30

Family

ID=36089824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/001081 WO2006032164A1 (fr) 2004-09-23 2004-09-23 Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2006032164A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514572A (ja) * 2015-04-30 2018-06-07 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
CN1365972A (zh) * 2001-01-19 2002-08-28 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CN1566091A (zh) * 2003-07-04 2005-01-19 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CN1365972A (zh) * 2001-01-19 2002-08-28 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
CN1566091A (zh) * 2003-07-04 2005-01-19 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI K ET AL: "Three dimensional quantitative structure-activity relationship of indolin-2-ones inhibitor against vascular endothelial growth factor receptors.", ACAD J SEC MIL MED UNIV., vol. 24, no. 12, 2003, pages 1334 - 1337 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514572A (ja) * 2015-04-30 2018-06-07 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物
US10370328B2 (en) 2015-04-30 2019-08-06 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof

Similar Documents

Publication Publication Date Title
KR100627611B1 (ko) 술폰아미드 함유 인돌 화합물
US8536184B2 (en) Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
CN102224142B (zh) 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物
EA022690B1 (ru) Имидазопиридиновые производные, способ их получения и терапевтическое использование
CN111303123B (zh) 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
KR101138840B1 (ko) 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
CN112300082B (zh) 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
WO2023280182A1 (fr) Composé servant d'inhibiteur de kat6
KR102286526B1 (ko) 헤테로시클릭-이미다졸계 화합물, 그 약물 조성물 및 그 제조방법과 용도
WO1999009986A1 (fr) Derives de 4-aminoquinazoline
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
WO2009100655A1 (fr) Dérivés de triazine à noyau aromatique et utilisations
CN110317173B (zh) 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
WO2006032164A1 (fr) Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci
CN115322158A (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
CN111848573B (zh) 苯并噻吩酰胺类化合物及其制备方法和用途
CN1566091A (zh) 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途
CN111763201A (zh) 苯并噻唑类化合物及医药用途
CN113072550A (zh) 一种高选择性成纤维细胞生长因子受体抑制剂和应用
CN101423513B (zh) 胺基嘧啶衍生物、及其制法和药物组合物与用途
CN111393363B (zh) 4-苯氧基喹啉并n-磺酰脒类化合物及其制备方法和用途
WO2019052046A1 (fr) Composé de quinazolines, son procédé de préparation et son application
WO2017097215A1 (fr) Inhibiteur de la voie wnt doté d'une structure urées
JP4623604B2 (ja) 新規なオキシインドール誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 04762214

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 4762214

Country of ref document: EP